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Summary
Objectives: To determine entry antibody seroprevalence and seroconversion to hepatitis C virus
(HCV) and associated risk factors in newly incarcerated prisoners.
Methods: Males and females entering South Australian prisons completed risk factor surveys and
were offered HCV-antibody testing. Participants completed additional surveys and, if HCV-negative
at last test, underwent further antibody tests at 3-monthly intervals for up to 15months. Datawere
analyzed using univariate and multivariate techniques.
Results: HCV seroprevalence among 662 prison entrants was estimated at 42%. Previous injecting
history was highly prevalent at entry (64%) and both community and prison injecting independently
predicted entry HCV status. Tattooing was not an important risk factor. While community exposure
could not be ruled out, three seroconversions were noted in 148 initially HCV-seronegative
individuals occurring in a median 121 days — 4.6 per 100 person-years. Prison injecting was
infrequently reported, but HCV-seropositive participants were significantly more likely to com-
mence IDU in prison than seronegative participants (p = 0.035).
Conclusions: Entry HCV seroprevalence in South Australian prisoners is extremely high and may
have contributed to a ‘ceiling effect’, minimizing the observable seroconversion rate. Greater
frequency of injecting among those already infected with HCV represents a significant threat to
other prisoners and prison staff.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.* Corresponding author. Current address: School of Health and
Social Development, Deakin University, 221 Burwood Highway, Bur-
wood, Victoria 3125, Australia. Tel.: +61 3 9244 6136;
fax: + 61 3 9244 6261.
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Hepatitis C virus (HCV) infection has an estimated Australian
prevalence of approximately 1.5%.1 In Australian prison
populations, however, prevalence estimates range from
around 35% to 50% overall and up to 67% in female prison-
ers.2—5 High prevalences have also been estimated for prison
populations around the world.6—10 Prison history has beenPublished by Elsevier Ltd. All rights reserved.
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tion,11,12 and it seems reasonable to assume some of this
risk is attributable to exposures occurring during incarcera-
tion. Nonetheless, there have been relatively few published
studies of HCV seroconversion in prison and these have
struggled to fully characterize disease acquisition in this
specific setting. Observed HCV seroconversion rates in prison
populations in Europe and the USA have ranged between one
and ten per 100 person-years.13—15 Case studies from Aus-
tralian prisons (in Victoria and New South Wales) have pro-
vided evidence of HCV seroconversions associated with
injecting drug use, fighting, and tattooing,16,17 and a sero-
conversion rate of 7.1 per 100 person-years has been esti-
mated in continuously detained prisoners (in New South
Wales).18 Injecting drug use (IDU) is thought to be the most
commonHCVrisk in prisoners,2,6,19 but prison-applied tattoos
have also been associated with infection.5 Sexual contact is
not considered an important mode of HCV transmission in
Australian prisoners.12 Reported seroconversion rates in
prison populations are relatively low compared to those
observed in community dwelling injecting drug users,20—23
but may highlight the difficulty of undertaking cohort studies
in highly mobile populations in which losses to follow-up are
common.
We have recently reported HCV antibody prevalence esti-
mates that were derived from a population-wide prison
health record audit,24 however there have been no other
published studies on HCV infection (prevalence or transmis-
sion) in South Australian (SA) prisons. Here we report the
findings of a cohort study that was aimed at estimating entry
HCV seroprevalence and seroconversion as well as associated
risk factors in SA prisoners.
Methods
Between October 2004 and August 2005, weekly recruitment
sessions were conducted in the reception areas of both of SA’s
metropolitan prisons for male prisoners. Recruitment ses-
sions were also held at the State’s only prison for females
between January and October 2005, where the shorter
recruitment period resulted from difficulties associated with
earlier recruitment strategies. Participation was offered to
all eligible prisoners remaining in prison on the day of the
session. Eligibility required participants be 18 years or older
and have the mental capacity to understand the purpose of
the study and provide a valid, signed consent. One of the
male prisons exclusively accommodated unsentenced prison-
ers, while the other prisons accommodated both sentenced
and unsentenced prisoners. The three prisons received
approximately 80% of all prison entrants to the jurisdiction’s
eight publicly operated prisons during the study period.
Participant follow-up occurred in all eight of the State’s
publicly operated prisons.
At recruitment, all participants completed a brief risk
factor survey about their pre-entry injecting and tattooing
history and were offered HCV-antibody testing. Where par-
ticipants had undergone testing within the prison system
within the previous three months (i.e., during previous per-
iods of incarceration) and results were available, additional
testing was not required. Testing was also not required from
participants with recent evidence of repeat positive serology,particularly in the case of poor vein health. Laboratory
serology reports filed within the participants’ prison health
records were considered evidence of HCV serostatus. HIV
status was not recorded in this cohort.
Participants completed risk factor surveys and, if remain-
ing seronegative, were offered additional HCV-antibody tests
at three-monthly intervals for up to 15 months or until
release. Seroconversion was accepted as evidence of newly
acquired infection and additional biochemical and virological
testing was not performed. Brief follow-up surveys (focusing
on injecting and tattooing behaviors since prison entry) were
completed only in the presence of the researcher or nursing
staff, who provided assistance where literacy was an issue.
All surveys were placed immediately in a sealed box before
being stored outside of the correctional system.
Correctional system assigned prisoner identification num-
bers were utilized to monitor prisoner movements within the
prison system and to link survey responses to health record
information. These identifiers were removed at the time of
analysis. Specimens were obtained by prison health staff, and
laboratory serology was performed by the Institute for Med-
ical and Veterinary Science in Adelaide, SA (by Abbott third
generation serologic assay). Quantitative data were analyzed
using Stata (release 8, Stata Corporation, College Station,
TX, USA). Kaplan—Meier survival estimates and log binomial
models also formed part of the analysis. Risk ratios and
seroconversion rates were generated and other statistical
methods were utilized as appropriate. All statistical tests
were performed at the 0.05 alpha level.
Formal approvals for the study were obtained from the SA
Aboriginal Health Research Ethics Committee, the SA Depart-
ment for Correctional Services Research Management Com-
mittee, the SA Department of Health Human Research Ethics
Committee, the Royal Adelaide Hospital Research Ethics
Committee, and the University of Adelaide Human Research
Ethics Committee.
Results
Therewere 1118 potentially eligible people remaining incar-
cerated at the weekly recruitment sessions, 126 of whom
were incarcerated more than once over the study period. It
was not possible to interview or assess the eligibility of 16%
(180/1118) of these individuals, with prolonged absences
due to court attendances being the main reason, followed
by prison-imposed time restrictions. Based on our recruit-
ment experience, 140 of these non-accessed individuals
(approximately 80%) might have ultimately had their
eligibility confirmed. Of the remaining 938 prisoners, 662
(71%) participated in the study — representing 61% of the
1078 eligible entrants. These rates are comparable to other
prison studies involving no participant incentives.8,14 Reluc-
tance to undergo a blood test was the most commonly
expressed reason for declining. Demographic information
about decliners was limited, however the sex distribution of
this group did not differ significantly from participants
( p = 0.351). The Mann—Whitney statistic associated with
the distribution of ranked prison ID numbers (serially allo-
cated at time of first imprisonment) was also not significant
( p = 0.745), suggesting little difference in previous incar-
ceration history between the two groups.
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(115/662) were Indigenous Australians (Aboriginal and/or
Torres Strait Islanders). Median age was 31.3 years and the
median time that participants were incarcerated during the
study period was 9.3 weeks, ranging from periods of 1 day to
70 weeks. These data were similar to available Australian
figures during the same period.25,26
Per incarcerated episode (55 participants were incarcer-
ated and recruited more than once, and three were recruited
a third time), discharge prior to 3 months occurred in 56%
(405/720) of cases; 76% (549/720) of discharges occurred
within 6 months of entry and 4% (30/720) were incarcerated
for twelvemonths or longer during the study period. Only two
participants were observed for as long as 15 months.
Sixty-four percent (423/662) of participants reported a
history of IDU in the community, and 27% (140/514) of those
who had been previously incarcerated reported having
injected while in prison. Nearly 60% (394/662) of prisonTable 1 Selected factors associated with HCV-antibody status a
(N = 524b)
Anti-HCV % (95% CI)
Sex
Female 59.3 (46.4—72.2)
Male 39.6 (35.1—44.0)
Median agec
>31 years 51.8 (42.6—57.4)
18—31 years 30.6 (21.4—34.4)
Indigenous status
Indigenous 60.2 (50.1—70.3)
Non-indigenous 37.5 (32.9—42.1)
Imprisonment history
Prison history 49.8 (44.9—54.6)
No prison history 10.3 (4.4—16.1)
Community injecting
Injected 58.3 (53.1—63.6)
Never injected 9.6 (5.1—13.9)
Prison injecting
Injected 84.9 (78.3—91.4)
Never injected 35.6 (30.1—41.1)
Community tattooing
Tattoos 49.7 (44.1—55.2)
No tattoos 29.5 (23.2—35.7)
Prison tattooing
Tattoos 76.0 (67.3—84.74)
No tattoos 42.1 (36.6—47.6)
HCV, hepatitis C virus; CI, confidence interval.
a At time of first enrolment (55 individuals re-enrolled on subsequen
b Excludes 138 individuals for whom entry HCV status could not be c
c Age at prison entry.entrants had tattoos that were applied in the community
and 23% (117/514) of those with a previous prison history had
tattoos applied while incarcerated. Almost 78% (514/662) of
participants had been previously imprisoned when they were
first enrolled in the study.
Entry HCV serostatus and risk factors
While antibody testing was offered at recruitment, 138
participants did not provide a specimen — most commonly
due their being released before a test could be arranged.
For some early release participants, entry HCV status
(particularly seronegativity) could be confirmed if they were
subsequently re-imprisoned during the study. Risk behaviors
reported at prison entry did not differ significantly between
those participants providing specimens and those not.
Overall entry HCV seroprevalence among 524 of the partici-
pants was 41.8% (95% CI 37.6—46.0%). Significant univariatemong prison entrantsa in South Australia; univariate analysis
Prevalence ratio (95% CI) p-Value (Chi-square)
1.50 (1.18—1.90) 0.004
1.69 (1.36—2.10) <0.001
1.61 (1.31—1.97) <0.001
4.84 (2.74—8.54) <0.001
6.12 (3.85—9.68) <0.001
2.38 (2.01—2.83) <0.001
1.69 (1.33—2.14) <0.001
1.81 (1.42—2.14) <0.001
t admissions).
onfirmed.
Table 2 Demographic and risk factors and HCV-antibody status in prison entrantsa in South Australia; multivariate analysis
(N = 404b)
Risk ratio (95% CIc) Risk difference (95% CIc) p-Value
Indigenous 1.24 (1.241—1.242) 0.13 (0.132—0.133) <0.001
Above median age (31 years) 1.29 (1.287—1.288) 0.12 (0.119—0.120) <0.001
Female 1.39 (1.313—1.482) 0.18 (0.125—0.241) <0.001
Prison IDU 1.61 (1.401—1.860) 0.37 (0.276—0.443) <0.001
Community IDU 4.10 (2.252—7.476) 0.29 (0.199—0.381) <0.001
HCV, hepatitis C virus; CI, confidence interval; IDU, injection drug use.
a At time of first enrolment (55 individuals re-enrolled on subsequent admissions).
b Excludes those for whom entry HCV-status could not be confirmed and those with no previous prison history.
c Three decimal places presented due to the narrowness of some confidence intervals.
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females, those aged above median age, Indigenous prison
entrants, and those with a history of previous imprisonment
(see Table 1). History of community injecting was associated
with the largest risk ratio (6.12) when compared to those
with no IDU history, and the risk ratio for community-applied
tattoos versus no tattoos was also significant. Among those
who had been previously imprisoned, prison injecting and
prison tattooing were both associated with significantly
higher risk than for those not reporting these behaviors.
Despite the significant univariate associations observed,
neither community nor prison applied tattoos were signi-
ficant predictors of HCV serostatus at prison entry after
adjustment for community and prison IDU. Both of the
latter practices remained highly predictive of HCV entry
seroprevalence after adjustment for tattooing in the same
log binomial model (data not shown). The adjusted risk
ratio for prison IDU was 1.66 (95% CI 1.39—1.98, p < 0.001)
and for community IDU was 3.65 (95% CI 2.25—5.93,
p < 0.001).
In a model including prison history and community risk
factors, adjusted ratios for community tattooing continued
to be non-significant but community IDU was significantly
associated with HCV antibody status (risk ratio = 4.77, 95% CI
3.01—7.56, p < 0.001). Prison history was independentlyTable 3 HCV risk behavior reported at each 3-monthly follow-up
Time of follow-up (months)
3 6
IDU since entry, n (%)
No injecting 165 (91.2) 94
IDU 16 (8.8) 15
Sharing needle, n (%) (prison IDU only)
No sharing 5 (31.3) 2
Shared 11 (68.8) 13
Tattoos applied since entry, n (%)
No tattoos 171 (94.5) 102
Applied tattoos 10 (5.5) 8
Sharing tattoo equipment, n (%) (prison tattoos only)
No sharing 7 (70) 8
Shared 3 (30) 0
HCV, hepatitis C virus; IDU, injection drug use.
a Includes individuals multiply enrolled in the study (164 individualsassociated with HCV serostatus at entry to prison after
adjusting for the other community risk factors (risk
ratio = 2.97, 95% CI 1.71—5.15, p < 0.001). A final model
including Indigenous status, age, sex, and community and
prison IDU demonstrated that each factor was an indepen-
dent predictor of HCV seropositivity (see Table 2), with
community IDU associated with the greatest risk (adjusted
risk ratio = 4.10).
Risk behaviors while incarcerated
Among the 191 participants remaining in prison beyond 3
months from recruitment, 423 follow-up contacts occurred.
Of these, 52% (221/423) occurred at the 3-month point. Some
participants either refused the questionnaire or the test
(where offered), but 85% (361/423) of follow-ups overall
resulted in a completed questionnaire.
IDU and tattooing behaviors reported by prisoners at
follow-up are summarized in Table 3. Injecting in prison
was relatively infrequently reported by participants overall,
but frequency increased with duration of imprisonment.
Disregarding multiply admitted prisoners, only 8% of parti-
cipants incarcerated for 3months reported having injected in
prison, while 26% of those remaining at 12 months had done
so (risk ratio = 2.98, 95% CI 1.23—7.22, p = 0.018). Overall,(N = 181a)
9 12
(86.2) 43 (86) 14 (73.7)
(13.8) 7 (14) 5 (26.3)
(13.3) 0 (00.0) 3 (60)
(86.7) 7 (100.0) 2 (40)
(92.7) 45 (88.2) 17 (89.5)
(7.3) 6 (11.8) 2 (10.5)
(100) 3 (50) 1 (50)
(0) 3 (50) 1 (50)
followed up at least once).
Figure 1 Time to commencing injection drug use (IDU) in
prison according to hepatitis C virus status at prison entry;
Kaplan—Meier estimates.
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having shared needles in prison.
Among those whose HCV serostatus was known, 15% (24/
160) reported IDU at some stage while incarcerated during
the study, and seroprevalence in this group was 79% (19/24).
HCV seroprevalence was 59% (80/136) in those reporting no
prison IDU. Those testing positive at entry appeared more
likely to report prison IDU than HCV-antibody negative par-
ticipants, albeit not significantly (risk ratio = 2.34, 2-sided
Fisher’s exact test p = 0.069). All prisoners reporting any
injecting in prison during the first 3 months of incarceration
had tested HCV-antibody positive at entry.
Using the Kaplan—Meier method, survival functions for
incarceration time until the first report of IDU in prison
differed according to HCV status at entry. As can be seen
in Figure 1, those testing HCV-antibody positive at prison
entry were more likely to commence prison IDU and contin-
ued to be at greater risk of IDU over time. The log-rank test
for equality of survivor functions was statistically significant
(Chi-square = 4.43, p = 0.035).
Three individuals (all males) were apparently initiated
into injecting while in prison, having reported no previous
community or prison IDU history. One reported injecting
within 6 months of prison entry, and the other two within
12 months. Two of these IDU initiates (aged 31 and 43 years)
had previous prison histories — one HCV seropositive and one
negative at prison entry. The other individual (aged 20 years)
was seronegative at entry with no history of previous impri-
sonment.
Tattooing in prison was also infrequently reported by the
participants (Table 3) with 11% of participants incarcerated
for 12 months reporting having applied tattoos in prison. This
was a greater proportion of tattooers relative to participants
followed up at three months, but the difference was not
statistically significant (risk ratio = 1.91, 2-sided Fisher’s
exact test p = 0.318). Only 16 individuals reported tattooing
during the study overall, of whom eight (50%) reported
sharing equipment.
Among those with confirmed serostatus, 8% (13/158)
reported tattooing at some stage during the follow-up per-
iod. HCV serostatus among these prison tattooers was 69% (9/
13), and was 61% (88/145) in those reporting no prison
tattooing. On univariate analysis, those testing positive at
entry were not more likely to report prison tattooing than
seronegative participants (risk ratio = 1.14, 2-sided Fisher’s
exact test p = 0.768).HCV seroconversion
One hundred and forty-eight of the participants testing HCV-
antibody negative at prison entry were available for follow-
up during a single or consecutive periods of incarceration
(median 121 days, range 2 to 419 days). Three seroconver-
sions were noted during this time — a seroconversion rate of
4.7 per 100 person-years (95% CI 3.4—6.1 per 100 person
years). Two seroconversions were noted at 3-month follow
up, in non-Indigenous males, aged 34 and 26 years at prison
entry. Both had spent approximately 106 days in prison since
testing negative at entry, but community exposure could not
be ruled out. Both reported no tattooing history and com-
munity IDU, but not prison IDU. The third seroconversion was
observed in a non-Indigenous male, aged 38 years, who was
HCV seronegative when first enrolled but seropositive when
enrolled a second time after having spent 34 days in the
community between admissions. Given the long seroconver-
sion period for HCV infection, it is feasible that his exposure
occurred prior to his first release to the community (following
80 days of incarceration), however the possibility of earlier
seroconversion cannot be excluded. This individual reported
a history of community and prison tattooing and community
IDU and reported having injected in prison for the first time
during his first enrolment in the study.
Discussion
This is the first study to investigate entry HCV seropreva-
lence, seroconversion, and risk factors in SA prisons and is
one of very few published studies on these issues in Australia
and around the world. High rates of population turnover and
difficulty controlling for prisoners leaving and re-entering
prison during follow-up have presented perhaps insurmoun-
table difficulties for transmission studies in this specific
setting. There is evidence that even more rapid population
turnover may occur in injecting drug users (those at greatest
HCV risk), who tend to be incarcerated more frequently, but
for the shorter periods associated with drug-related
offences.27 The use of prisoner identification numbers in this
study may have minimized some losses to follow-up among
prisoners readmitted during the observation period.
HCV seroprevalence at prison entry
Similar to other Australian studies,2—5,28 this study esti-
mated an HCV seroprevalence in prison entrants of 42%. In
high prevalence populations, such as prisoners, the presence
of HCV-antibody is known to be highly correlated with vir-
emia.29 Our finding of increased HCV risk with age is con-
sistent with the literature,11,15,30 and is likely to be related
to greater duration of exposure. Much of the literature also
supports our finding of increased risk for female prison-
ers,2,4,5,9,31 and the greater proportion of female prisoners
charged with drug-related offences relative to males32—34 is
commonly proposed to explain the sex differential. Our
study, however, found sex was independently associated
with entry HCV serostatus after adjusting for IDU history
and other factors. Other authors have also identified excess
HCV cases in female prisoners after controlling for other
factors2 as well as little evidence that HCV seroprevalence
206 E.R. Miller et al.among females differs according to the nature of the
offence.35 It is possible that there are factors, behavioral
or other, that increase the HCVrisk associated with injecting
in females.
In contrast to other Australian studies,2,3,28 we found
significantly increased risk for Indigenous prisoners. Our
previous report also noted increased HCV risk in Indigenous
prisoners originating from metropolitan areas but reduced
risk for Indigenous prisoners from remote areas in SA.24 The
present study, in metropolitan prisons, further supports the
proposal of geographical differences in the risk profile of
Indigenous communities.
We have found that any IDU history, in the community or
during previous imprisonments, independently predicted
entry HCV serostatus. Consistent with the Canadian experi-
ence,8 we found that community IDU, rather than prison IDU,
was associated with the greatest risk after adjusting for age,
sex, and Indigenous status. While tattoos were common
among SA prison entrants, neither community nor prison
applied tattoos were predictive of entry HCV serostatus after
adjustment for IDU.
In this study, SA prisoners modified their risk behavior
during their incarceration. If true of prison populations
elsewhere, reduced frequency of risk behaviors may par-
tially explain why transmission studies have tended to
observe low seroconversion rates in prisoners relative to
those observed in community-dwelling injecting drug
users.20—23 Prison injecting was infrequently reported over-
all but was more frequently reported in participants identi-
fied as HCV seropositive at entry, and this group was
significantly more likely to commence injecting over time.
Given that sharing needles in prison was reported by the vast
majority of prison injectors, and syringes and needles tend
to be used and reused by a large number of prisoners,36,37
there appear to be some safety implications for prisoners
and prison officers. While few in number, prison IDU was also
reported by HCV seronegative individuals and three parti-
cipants in this study reported prison injecting for the first
time. The HCV risk associated with susceptible individuals
sharing contaminated needles in prison cannot be over-
stated.
Tattooing behaviors, not associated with HCV serostatus in
this population, were also apparently modified by incarcera-
tion. Sixty percent of prison entrants reported having com-
munity applied tattoos but only 9% reported tattooing during
the study, the majority of whom reported not sharing tattoo-
ing equipment. Boredom has been suggested as a principal
motivation for prison tattooing.17 SA prisoners spend many
hours confined to their cells and some might use this time
engaging in solitary tattooing — minimizing the opportunity
for sharing equipment. Tattoo application method may
further reduce the HCV risk associated with tattooing. It
has been reported that sewing needles are commonly used
for prison tattooing,11 yet it is possible that solid needles may
not efficiently transmit HCV.38
Supporting findings elsewhere,9,11,39,40 we found that
previous imprisonment independently predicts HCV seropo-
sitivity at entry. It is not clear what the precise mechanism
for HCVacquisition might be, but it is possibly related to high
background HCV prevalence. This would result in greater
exposure risks associated with blood prone activities, such as
physical altercations.16HCV seroconversion in SA prisoners
A relatively low HCV seroconversion rate was observed in this
study with uncertainty surrounding the location of exposure
in all three of the seroconversions noted. Nonetheless, the
calculated rate of 4.6 per 100 person-years was comparable
to the published literature in this area.13,14,18,41 It is possible
that the low rate observed is due to a ‘ceiling effect,’ given
the high background HCV seroprevalence in this population.
At entry, up to 42% of prison entrants were positive for HCV-
antibody and up to 64% reported having a pre-entry IDU
history. As suggested in one US study,30 low HCV incidence
rates in prisoners may be due to a ‘saturation’ of the popula-
tion — with those likely to inject in prison already having
seroconverted prior to entry. Relatively low frequency of
prison injecting was also a characteristic of this study popu-
lation.
Nonetheless, prison exposure cannot be ruled out as a
major contributor to HCV seroprevalence in this at risk group.
This is because non-returning participants were lost to fol-
low-up once they were released to the community. Since
drug-related offences are associated with relatively short
incarceration periods, losses to follow-up were greater in the
group with, potentially, the greatest risk for HCV.
Limitations of this study
Due to the high frequency of illiteracy, it was not always
possible for participants to respond to the questionnaire
without assistance. While all participants were advised that
information provided by them would not be passed on to
correctional staff, self-reporting clandestine activity is
known to be difficult for some participants.42
As a result of high entry HCV seroprevalence, the number
of susceptible individuals in this study may have been too few
to detect prison-exposed HCV seroconversions. Combined
with a long seroconversion window and rapid population
turnover (resulting in relatively short periods of follow-
up), this ‘ceiling effect’ may represent an almost insurmoun-
table problem for studying transmission in this particular
population. Compounding this difficulty was the relatively
small size of the SA incarcerated population — reported to
number approximately 1500 on any given day during the time
of the study.25 Nonetheless, three seroconversions were
identified and the HCV serostatus of a number of returning
participants was confirmed. The latter was made possible by
the study design, which allowed for the detection of parti-
cipants if they came back into prison. This design might be
effectively employed in larger prison populations on this or
other issues of public health importance.
Conclusions
This study estimated high HCV seroprevalence in the SA
prisoners, especially in women, indigenous persons, and
injection drug users. The seroconversion rate for HCV-nega-
tive entrants was low. Of most concern was that HCV ser-
opositive prison entrants were significantly more likely to
commence injecting while incarcerated and that needle
sharing was common in this group. This suggests that each
needle currently in circulation within the SA prison system
HCV infection in South Australian prisoners 207will almost certainly be contaminated with HCV, which has
serious implications for prison staff and also for susceptible
prisoners.
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